Navigation Links
ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
Date:8/28/2012

SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012 at 2:25 p.m. Eastern time, in the Starlight Center Salon at The Waldorf Astoria hotel in New York City.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function which is compromised in a wide range of serious and life-threatening diseases and conditions.  The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Announces Appointment Of Chief Medical Officer
2. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
3. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
4. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
5. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
6. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
7. Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer
8. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
9. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
10. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
11. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
(Date:4/27/2016)... April 27, 2016 Elekta today ... platform will be the focal point of seven scientific ... European Society for Radiotherapy & Oncology, taking place April ... a state-of-the-art radiotherapy system and a high-field MRI scanner ... see the patient,s anatomy in real time. The MR-linac ...
(Date:4/27/2016)... , April 27, 2016   Zillion ... digital health technology platform, which specializes in live ... into scalable digital products, Zillion enables companies to ... empower consumers to take control of their health. ... video conferencing – including one-to-one, group and webcast ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. ... of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death ... podcasted thereafter . Dr. Bernie Siegel, author of a plethora of essential ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... ... ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of skin ... More than 10,000 people are expected to die of melanoma this year. The risk increases ... of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, ... round of funding led by Eastside Partners, with participation from existing investor Martin ... customer base and accelerate its technology and product roadmap. , “Jvion ...
(Date:4/29/2016)... ... ... Nike Softball Camp at the College of Brockport in New York is ... 10-18. All facets of the game will be covered; hitting, fielding, base-running, and team ... the finest softball facilities in the region. The outstanding professional college staff complement and ...
Breaking Medicine News(10 mins):